



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Novel SARS-CoV-2/COVID-19: Origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis



Yasmeen Junejo^a, Mehmet Ozaslan^{b,*}, Muhamad Safdar^{b,c,**}, Rozhgar A. Khailany^{d,e},
SaifUr Rehman^f, Wasim Yousaf^g, Musarrat Abbas Khan^c

^a Department of Physiology and Biochemistry, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan

^b Department of Biology, Division of Molecular Biology and Genetics, Gaziantep University, 27310 Gaziantep, Turkey

^c Department of Breeding and Genetics, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan

^d Department of Biology, College of Science, Salahaddin University-Erbil, Iraq

^e Department of Biology, Faculty of Education, Tishk International University, Erbil, Iraq

^f State Key Laboratory for Conservation and Utilization of Subtropical Agro-bioresources of Guangxi University, Nanning 530005, China

^g Institute of Animal and Dairy Sciences, Faculty of Animal Husbandry, University of Agriculture, Faisalabad, Pakistan

ARTICLE INFO

Keywords:

SARS-CoV-2

Origin

Pathogenesis

Variations

Evolution

Phylogenetic analysis

ABSTRACT

In this review, we focused on the origins of the novel coronavirus (SARS-CoV-2), origin, pathogenesis, immune responses, genes and genetic variations, phylogenetic analyses, and potential therapeutic strategies to summarize approaches for developing broadly effective preventions and vaccines to cope COVID-19. Towards the end of 2019, SARS-CoV-2 has emerged in association with the SARS, later was named COVID-19 caused an environment of chaos worldwide and infected a massive number of lives. Since these epidemics or pandemics had spread to 210 countries and territories around the world and 2 international conveyances with 6,467,229 confirmed cases, including, 382,766 deaths, as of June 03, 2020 (<https://www.worldometers.info/coronavirus/>), hence the World Health Organization declared it as a global Public Health Emergency. There are no clinically approved vaccines or antiviral drugs available for either of new or old corona infections; thus, the development of effective therapeutic and preventive strategies that can be readily available to cope with these strains.

1. Introduction

Before December 2019, very little was known about the coronaviruses (CoVs) because previously CoVs were not hit the global community so badly even though CoVs have been infected many species including humans and discussed for more than 70 years. Bailey et al. (1949) were reported murine virus (JHM) for the first time in 1949. Molecular mechanisms and pathogenesis of different CoVs have been intensely studied in different animal species such as porcine transmissible gastroenteritis virus (TGEV), bovine coronavirus (BCoV), and avian infectious bronchitis viruses (IBV). The CoVs having emergence and re-emergence history causing respiratory and intestinal infections in animals and humans (Masters and Perlman, 2013). This family of viruses remained unclear because they can only cause common cold symptoms in immune-competent individuals until the outbreak of

severe acute respiratory syndrome (SARS) in 2003 (Weiss and Navas-Martin, 2005). Before the SARS epidemic in 2002–03, it was supposed that CoVs are not deadly pathogens to humans. Subsequently, a decade later in 2012, another Zoonotic highly pathogenic coronavirus emerged in Middle Eastern countries caused the Middle East respiratory syndrome (MERS) epidemic (Zaki et al., 2012). The ongoing SARS-CoV-2 pandemic situation got worldwide attention and became the utmost priority of the global health community due to the higher rate of human-human transmission. Previous studies have confirmed that SARS-CoV-2 adopted recombination and mutations strategies that help to adapt rapidly changing host environments through genotype adjustment via reproductive adaptability and ultimately escape from human immune reconnaissance (Rehman et al., 2020).

In a broader perspective, this review will describe the SARS-CoV-2 origins, epidemiology, pathogenesis, clinical manifestations, immune

Abbreviations: COVID-19, Coronavirus Disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization; TGEV, transmissible gastroenteritis virus; BCoV, bovine coronavirus; IBV, avian infectious bronchitis viruses; ACE2, angiotensin receptor 2

* Correspondence to: M. Ozaslan, Department of Biology, Gaziantep University, 27310 Gaziantep, Turkey.

** Correspondence to: M. Safdar, Department of Breeding and Genetics, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan.

E-mail addresses: ozaslanmd@gantep.edu.tr (M. Ozaslan), safdar@cuvas.edu.pk (M. Safdar).

<https://doi.org/10.1016/j.genrep.2020.100752>

Received 5 June 2020; Accepted 11 June 2020

Available online 15 June 2020

2452-0144/ © 2020 Elsevier Inc. All rights reserved.




Fig. 1. Classification of coronaviruses.

enhancement, genes and their variations, phylogenetic analyses, potential therapeutic strategies and future perspective to summarize approaches for developing broadly effective prevention of Corona Virus Disease-19 (COVID-19).

2. Origin

Coronaviridae family divided into two subfamilies, the coronaviruses, and the toroviruses. All identified CoVs are categorized into four different genera *alpha coronaviruses*, *beta coronaviruses*, *gamma coronaviruses*, and *delta coronaviruses*. The human infecting CoVs belongs to *alpha coronaviruses* and *beta coronaviruses*, whereas *gamma coronaviruses*, and *delta coronaviruses* showed susceptibility for fish and birds as shown in Fig. 1.

All human infecting CoVs can cause mild to severe infection in humans and used spillover intermediate hosts (Fig. 2). Earlier to 2019, there were only six CoVs that were known to infect humans and cause respiratory diseases. Four out of six (HCoV-229E, HCoV-OC43, HCoV-NL63, and HKU1) human infecting CoVs can only cause mild upper respiratory disease, and in rare cases, some of them can cause severe infection in infants, young children, and elders (Fig. 2). Although, SARS-CoV and MERS-CoV which are zoonotic in origin can infect the lower respiratory tract and cause a severe respiratory syndrome in humans (Chang et al., 2006; N. Chen et al., 2020; Woo et al., 2012). Previously studied known pathogenic coronaviruses are presented in the table (Table 1).

SARS and the MERSCoVs belong to *beta coronaviruses* have been characterized as they were transmitted from animals to humans and caused severe disease outbreaks in the past. SARS-CoV was transmitted in humans from bats via the intermediary host of palm civet cats (Fig. 2) in the Guangdong province of China and about 8422 infected cases with 916 deaths were recorded and the mortality rate was 11%. Furthermore, a decade later in 2012, a bat origin virus MERS-CoV epidemic was emerged in Saudi Arabia through the dromedary camels (Fig. 2) and caused 858 deaths out of 2494 infected people with a 34% fatality rate (Singhal, 2020).

Now, in late December 2019, a couple of patients were diagnosed with concentrated pneumonia with an unknown etiology in Wuhan, China (Bogoch et al., 2020; Hui et al., 2019; Lu et al., 2020). The newly

emerged novel CoV retained 99.8–99.9% nucleotide sequence homology with *beta bat CoVs* that directed the reemergence of another viral strain, later entitled as SARS-CoV-2 (Ren et al., 2020) and genetic analysis of the SARS-CoV-2 represented genetic similarity 50% with MERS-CoV and 80% with SARS-CoV (Lu et al., 2020; Ren et al., 2020; Rehman et al., 2020).

3. Epidemiology

As of 03 June 2020, a total of 6,467,229 cases of COVID-19 have been confirmed worldwide including 382,766 deaths (WHO, 2020). COVID-19 as an acute respiratory infectious disease, primarily spreads by the mean of the respiratory tract, via droplets, respiratory secretions emitted from an infected person or direct contact for a low infective dose (Li et al., 2020; Lee and Hsueh, 2020). Significantly high level of viral loads was also observed in the nasal cavity as compared to the throat where the viral load was the same between symptomatic and asymptomatic people (Zou et al., 2020). Patients can be a career of infection even on clinical recovery and few people may act as a strong candidate to spread the infection, for example, an infected UK resident caused 11 people to infect by COVID-19. The incubation period of this disease ranges from 2 to 14 days (median 5 days) (Singhal, 2020). SARS-CoV-2 virus responds to the same receptor, angiotensin receptor 2 (ACE2), to enter the respiratory mucosa as the SARS-CoV entry receptor (Cheng and Shan, 2020).

4. Pathogenesis

The SARS-CoV-2 is a respiratory system targeting virus therefore the prime pathogenesis of the COVID-19 severe pneumonia, RNAemia, combined with the incidence of ground-glass opacities, and acute cardiac injury. Also, some patients were exhibited non-respiratory symptoms such as the acute liver and heart injury, kidney failure, diarrhea, implying multiple organ involvement (Y. Chen et al., 2020; G. Guan et al., 2020; C. Huang et al., 2020; P. Huang et al., 2020; Su et al., 2016; W. Wang et al., 2020). Crucially, viral replication is supposed to occur in the mucosal epithelium of the upper respiratory tract (nasal cavity and pharynx), in addition, proliferation is in the lower respiratory tract and gastrointestinal mucosa that results in the mild viremia (Xiao et al.,




Fig. 2. Human infection-causing coronavirus and their origin.

2020; Yuefei et al., 2020). Fig. 3 is a hypothetical explanation of the pathogenesis of SARS-CoV-2 infection.

5. Clinical manifestations

The clinical features of COVID-19 range from an asymptomatic condition to acute respiratory distress syndrome and multiple organ dysfunction, so it is difficult to distinguish it from other respiratory infections. Almost 5.2 days' time period of incubation is required for the

appearance of COVID-19 symptoms (Li et al., 2020), and after one week of the onset of disease patients experience pneumonia, the respiratory failure that leads to death (N. Chen et al., 2020). The primary and common symptoms at the early stage of COVID-19 infection are fever, cough, and fatigue, whereas other symptoms such as sputum, headache, hemoptysis, diarrhea, dyspnoea, and lymphopenia have also been observed (Carlos et al., 2020; W.-j. Guan et al., 2020; P. Huang et al., 2020; Ozaslan et al., 2020; Guan et al., 2020; D. Wang et al., 2020). Clinical findings related to acute lung injury, ARDS, shock, kidney

Table 1

Pathogenic coronaviruses, strain, host, and disease symptoms.

Accession no.	Virus	Strain	Host	Symptoms
NC_002645.1	Human CoV-229E	HCoV-229E	Human	Mild respiratory tract infections
NC_005831.2	Human CoV-NL63	HCoV-NL63	Human	Mild respiratory tract infections
MH940245.1	Human CoV-HKU1	HCoV-HKU1	Human	Pneumonia
KU131570.1	Human coronavirus OC43 strain	Human CoV-OC43	Human	Mild respiratory tract infections
AY345986	Severe acute respiratory syndrome	SARS-CoV	Human	Severe acute respiratory syndrome, 10% mortality rate
NC_045512.2	Severe acute respiratory syndrome coronavirus 2	SARS-CoV-2	Human	Fever, Cough, Shortness of breath or difficulty breathing
MN988668.1	Wuhan seafood market pneumonia virus isolate 2019-nCoV WHU01	2019-nCoV WHU01	Human	Severe acute respiratory syndrome
MH734115.1	Middle East respiratory syndrome coronavirus	MERS-CoV	Human	Severe acute respiratory syndrome, 37% mortality rate
DQ811787.1	Porcine respiratory coronavirus	PRCV/ISU-1	Pig	Mild respiratory tract infections
NC_038861.1	Transmissible gastroenteritis virus	TGEV/PUR46-MAD	Pig	Diarrhea, with 100% mortality in piglets less than 2-week-old
KU558701	Porcine epidemic diarrhea virus	PEDV/ZJU-G1-2013	Pig	Severe watery diarrhea
KU558701	Swine enteric alphacoronavirus	SeACoV-CH/GD-01	Pig	Severe and acute diarrhea and acute vomiting
NTU336/F/2008	Canine CoV	CCOV	Dog	Mild clinical signs, diarrhea
DQ848678.1	Feline infectious peritonitis virus	FCoV C1Je	Cat	Fever, vasculitis, and serositis, with or without effusions
EF424623	Bovine CoV/ENT	Bovine CoV/ENT	Cow	Diarrhea
AY394989	Equine Severe acute respiratory syndrome	EquineCoV/Obihiro12-1	Horse	Fever, anorexia, leucopenia
NC_001846.1	Mouse hepatitis virus strain MHV-A59 C12	MHV-A59	Mouse	Acute pneumonia and severe lung injuries
NC_010646	Beluga whale coronavirus SW1	Beluga Whale CoV/SW1	Whale	Pulmonary disease, terminal acute liver failure
M21883	infectious bronchitis virus strain	IBV	Chicken	Severe respiratory disease
NC_011547.1	Bulbul CoV HKU11-934	HKU11-934	Bulbul	Respiratory disease (collected from the respiratory tract of dead wild birds)
NC_009657	Sparrow coronavirus HKU17	HKU17	Sparrow	Respiratory disease (collected from the respiratory tract of dead wild birds)
MG772934.1	Bat SARS-like coronavirus	Bat-SL-CoVZXC21	Bat	Fever, Cough, Shortness of breath or difficulty breathing
MG772933.1	Bat SARS-like coronavirus	Bat-SL-CoVZC45	Bat	Fever, Cough, Shortness of breath or difficulty breathing




Fig. 3. Pathogenesis of SARS-CoV-2 infection.

injury can cause death (Carlos et al., 2020; Ozaslan et al., 2020; Phan et al., 2020). The shorter period was witnessed in patients with the age of more than 70-years old (Carlos et al., 2020). Incompatible death results are more common in the elderly and those with underlying comorbidities (50–75% of fatal cases). In the adult, aged patient's fatality rate ranges between 4 and 11% while the overall fatality rate varies between 2 and 3% (Ozaslan et al., 2020; Rothan and Byrareddy, 2020).

In another study, similar symptoms for COVID-19 and earlier *betacoronavirus* have been observed in chest CT scans (P. Huang et al., 2020). Although, some distinctive clinical features in COVID-19 exist including lower airway and upper respiratory tract symptoms like rhinorrhea, sneezing, and throat sores (Assiri et al., 2013; Lee et al., 2003). Similarly, chest radiography of some patients showed an infiltrate in the upper lobe of the patients (Phan et al., 2020). Whereas, gastrointestinal symptoms like diarrhea were also diagnosed in some COVID-19 patients (Gu et al., 2020), which were also found in MERS-CoV or SARS-CoV patients (Assiri et al., 2013; Lee et al., 2003).

6. Immune enhancement against COVID-19

Antibody-dependent enhancement (ADE) occurs when non-neutralizing antiviral proteins facilitate virus entry into host cells, leading to increased infectivity in the cells. Recently, ADE is proposed as a responsible for the inflammation because of SARS-CoV-2 infection (Fu et al., 2020). ADE can interact with virus-antibody complexes their receptors, and increasing the target cell infection (Takada and Kawaoka, 2003). The interaction between specific receptor and virus complex can activate both pathways such as inflammatory responses and viral replication in the patients (Gu et al., 2020). In another study, loss of ACE2 function is related to acute lung injury because the ACE2 downregulation can result in RAS dysfunction, and endorse the inflammation that causes vascular permeability (Imai et al., 2008).

These biomarkers propose both a molecular description and a feasible treatment for acute respiratory distress syndrome (ARDS) following SARS-CoV-2 infection. Moreover, in severe cases, CD4 and CD8 T cells exhibited hyper-activation and high level of expression of cytotoxic granules CD8 T cells and pro-inflammatory CD4 T cells suggested immune responses against viral attack (Xu et al., 2020). Additionally, lymphopenia is also reported as a common characteristic of COVID-19 which is a serious reason account for severe infection and a higher rate of mortality (P. Huang et al., 2020; Zhu et al., 2020). The virus can remain viable on surfaces in suitable conditions and can be smashed within 60 s by common disinfectants like sodium hypochlorite and hydrogen peroxide (Kampf et al., 2020).

7. Genes involved

Interestingly, the histopathologically ARDS has been identified in the patients of all type of cases such as SARS-CoV, MERS-CoV, and SARS-CoV-2 (Ding et al., 2003; Ng et al., 2016; Xu et al., 2020). Elevated levels of cytokines and chemokines in COVID-19 patients including IL1 β , IL1RA, IL7, IL8, IL9, IL10, basic FGF2, GCSF, GMCSF, IFN γ , IP10, MCP1, MIP1 α , MIP1 β , PDGFB, TNF α , and VEGFA were also observed. Additionally, a few patients with a severe infection in the intensive care unit also showed increased levels of pro-inflammatory cytokines including IL2, IL7, IL10, GCSF, IP10, MCP1, MIP1 α , and TNF α that were responsible for disease severity (P. Huang et al., 2020). After genetic variability, the cytokines were studied and the incidence of ARDS was evidenced. Many candidate genes, i.e. ACE2, IL-10, TNF, VEGF are believed to be associated with ARDS development or outcome (Meyer and Christie, 2013). In addition, the increased levels of IL-6 and IL-8 were confirmed to be associated with ARDS (Thompson et al., 2017).

8. Genomic variations in SARS-CoV-2

The genetic information of any life is preserved in its genome, and the annotation is the first step to explain the sequence. While the length of the SARS-CoV genome is above ~29 kb, it appears that only a few coding genes do not match the general characteristics of the viral genome and the group of minimal hereditary data. In previous studies, 156 variants were found in 95 samples available on NCBI databases and 116 variants were identified uniquely. In addition, these variants have 46 missense, 52 synonymous, 2 insertions, 1 deletion, and 14 non-coding alleles. The most common variant were found 8782C > T (ORF1ab) in 13 samples, 28144T > C (ORF8) in 14 samples and 29095C > T (N) in 8 samples. The 8782C > T and 28144T > C coincided. Also, 29095C > T was located in one of these subsets. Both 8782C > T and 29095C > T were synonymous; However, 28144T > C causes amino acids to replace L84S in ORF8. For 46 missense variants, ORF1ab has 24 variants, that occupies 2/3 of the entire genome. All non-coding mutations are within 3'UTR or 5'UTR regions that have C > T changes (Rozhgar et al., 2020).

In another study, Rehman et al. (2020) were compared the Envelop (E), Nucleocapsid, Membrane (M), and Spike protein of SARS-CoV-2 with SARS-CoV. It represented 7%, 8%, 7% and 19% amino acid sequence variations in E, M, N and S regions respectively (Table 2). Moreover, they also presented nine putative recombinants in SARS-CoV-2 and hypothesized that SARS-CoV-2 is the recombinant of SARS and SARS-like CoVs. Six out of nine recombinants are in S motif which is important for viral pathogenicity. Furthermore, SARS-CoV-2 receptor-binding domain (RBD) was analyzed and showed 73% sequence similarity with the pandemic RBD (Rehman et al., 2020). While the binding free energies that were calculated for human ACE2 and S protein binding complexes and SARS-CoV-2 free binding energy increased up to 28 kcal mol⁻¹, representing higher binding affinity to the human ACE2 receptor (Rehman et al., 2020).

9. Evolution of SARS-CoV-2

Distinguishing the origins of an emerging pathogen can be critical during the beginning periods of an outbreak as it may allow for containment measures to be precisely targeted. Before December 2019, four strains of Betacoronavirus, HKU1, MERS-CoV, OC43, and SARS-CoV, had been accounted to cause severe human infections (Paola et al., 2020). The fifth strain, a novel beta coronavirus SARS-CoV-2 causing human pneumonia, was first detailed in Wuhan, Central China (Paola et al., 2020). Coronaviruses are naturally hosted and developmentally formed by bats. To do this, it has been proposed that the majority of human coronaviruses are derived from the bat reservoir (Tang et al., 2020). Several teams have recently confirmed the genetic similarity between SARS-CoV-2 and the beta betacoronavirus of the subgenus Sarbecovirus (Tang et al., 2020). The genome sequence of the new virus is 96.2% identical to that of the bat. SARS-related coronavirus (SARSr-CoV; RaTG13) has been collected in Wuhan, China, but is not identical to the genome of SARS-CoV (about 79%) or MERS-CoV (approximately 50%) as shown in Fig. 4. Replacement and recombination of nucleotides has been proposed a mechanism of viral development in nature (Rehman et al., 2020; Phan, 2020).

In addition, SARS-CoV-2 uses the same receptor, angiotensin II

converting enzyme (ACE2) as SARS-CoV. Although the specific pathway of transmission from natural reservoirs to humans is unclear (Peter et al., 2020; Tang et al., 2020), several studies have shown that pangolin may confer partial spike genes to SARS-CoV-2; The critical functional regions of the spike protein SAR-CoV-2 are nearly the same as those defined in viruses isolated from a pangolin (Tang et al., 2020).

10. Potential therapeutic strategies

In the early era until 1960 CoVs were thought to be simple viruses causing flu-like symptoms. In later studies, it was proved that CoV is a more serious and dangerous virus and it causes SARS epidemics (2002 to 2003) (Cascella et al., 2020; Li et al., 2020; W. Wang et al., 2020). The outbreak of MERS in Middle Eastern Countries in 2012 posed a very serious condition that proved it more dangerous (Burke et al., 2020; Cascella et al., 2020; Li et al., 2020; W. Wang et al., 2020).

To manage the COVID-19 antipyretics and analgesics are directed. Moreover, hydration is maintained and also the respiratory system is supported by mechanical ventilation or extracorporeal membrane oxygenation. In case of bacterial infection along with COVID-19 antibiotics are found beneficial. We may use chloroquine and hydroxy-chloroquine having synergistic effects, but further studies needed (De Wit et al., 2020; Ozaslan et al., 2020). Also, we have the option of Favipiravir and Remdesivir which were trialed by China and Japan but further studies are required (Fu et al., 2020; Hui et al., 2020).

Also, many evidences showed that convalescent plasma from patients recovering from viral infections can be used as a treatment in patients infected with SARS-CoV-2 (Chen et al., 2020). In addition, by influencing ACE2 levels, cardiovascular diseases and/or their treatment can play an important role in the infectivity and consequences of COVID - 19. Whether ACE2 treatment or upregulation caused by the disease immediately affects the COVID - 19 course (Sommerstein et al., 2020). During this global emergency of the COVID-19 pandemic, strategies are taken into account to quickly monitor the timeline for licensing a vaccine against COVID-19, especially by compressing the generally long duration of phase II-III study (Callaway, 2020; De Wit et al., 2020; Boodman, 2020; Eyal et al., 2020).

11. Conclusion

It is widely accepted that there are many viruses in their natural reservoirs for a very long time. The constant spread of viruses from natural hosts to humans and other animals is largely due to human activities. Data collected on genetic evolution, receptor binding and pathogenesis have shown that SARS-CoV is most likely caused by bats by sequential recombination of bat SARS-CoVs. The rapid proliferation of SARS-CoV-2 raises many questions, whether its development is driven by the mutation or any other mechanisms. So the Government and health authorities must develop and implement the guidelines for researchers and the public for the development of drugs and vaccines to reduce the spread rate of COVID-19.

Acknowledgments

We highly appreciate many members of the frontline medical and nursing staff who demonstrated selfless and heroic devotion to duty in

Table 2
SARS-CoV-2 homology and genetic variations in different genomic regions with respect to SARS-CoV.

Envelop protein		Membrane protein		Nucleocapsid protein		Spike protein	
Homology	Genetic variations	Homology	Genetic variations	Homology	Genetic variations	Homology	Genetic variations
93%	07%	92%	08%	93%	07%	81%	19%

SARS-CoV-2 (Wuhan-Hu-1-CoV) and SARS-CoV (GZ02).




Fig. 4. Whole genome-based phylogenetic tree of CoVs constructed with the maximum-likelihood method using BEAST with GTR + I + G as the nucleotide model of substitution.

the face of this outbreak.

Data availability statement

All relevant data are within the manuscript.

Funding

The authors received no specific funding for this work.

Declaration of competing interest

The authors have declared that no competing interests exist.

Ethical approval

We have followed all ethical approvals for this study.

Informed consent

All authors have read and approved the contents and manuscript.

References

- Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A., Al-Rabiah, F.A., Al-Hajjar, S., Al-Barrak, A., Fieban, H., Al-Nassir, W.N., Balkhy, H.H., Al-Hakeem, R.F., 2013. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect. Dis.* 13 (9), 752–761.
- Bailey, O.T., Pappenheimer, A.M., Cheever, F.S., Daniels, J.B., 1949. Amurinevirus (JHM) causing disseminated encephalomyelitis with extensive destruction of myelin: II. Pathology. *J. Exp. Med.* 90 (3), 195–212.
- Bogoch, I.I., Watts, A., Thomas-Bachli, A., Huber, C., Kraemer, M.U., Khan, K., 2020.

- Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel. *J. Travel Med.* <https://doi.org/10.1093/jtm/taaa1008>.
- Boodman, Eric, 2020. Coronavirus Vaccine Clinical Trial Starting Without Usual Animal Data. *STAT* (Retrieved 19 April 2020).
- Burke, R.M., Midgley, C.M., Dratch, A., Fenstersheib, M., Haupt, T., Holshue, M., et al., 2020. Active monitoring of persons exposed to patients with confirmed COVID-19 — United States. *MMWR Morb. Mortal. Wkly Rep.* <https://doi.org/10.15585/mmwr.mm6909e1externalicon>.
- Callaway, E., 2020. Should scientists infect healthy people with the coronavirus to test vaccines? *Nature* 580 (7801), 17. <https://doi.org/10.1038/d41586-020-00927-3>.
- Carlos, W.G., Dela Cruz, C.S., Cao, B., Pasnick, S., Jamil, S., 2020. Novel Wuhan (2019-nCoV) coronavirus. *AmJRespirCritCareMed* 201 (4), 7–8.
- Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C., 2020. Napoli RD: Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls Publishing, Treasure Island, FL.
- Chang, C.-k., Sue, S.-C., Yu, T.-h., Hsieh, C.-M., Tsai, C.-K., Chiang, Y.-C., Lee, S.-j., Hsiao, H.-h., Wu, W.-J., Chang, W.-L., 2006. Modular organization of SARS coronavirus nucleocapsid protein. *J. Biomed. Sci.* 13 (1), 59–72.
- Chen, L., Xiong, J., Bao, L., Shi, Y., 2020. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect. Dis.* [https://doi.org/10.1016/s1473-3099\(20\)30141-9](https://doi.org/10.1016/s1473-3099(20)30141-9).
- Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., 2020a. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* 395 (10223), 507–513.
- Chen, Y., Liu, Q., Guo, D., 2020b. Emerging coronaviruses: genome structure, replication, and pathogenesis. *J. Med. Virol.* 92 (4), 418–423.
- Cheng, Z.J., Shan, J., 2020. 2019 novel coronavirus: where we are and what we know. *Infection* 48, 155–163.
- De Wit, E., Feldmann, F., Cronin, J., Jordan, R., Okumura, A., Thomas, T., Scott, D., Cihlar, T., Feldmann, H., 2020. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. *Proc. Natl. Acad. Sci. U. S. A.* 117 (12), 6771–6776. <https://doi.org/10.1073/pnas.1922083117>.
- Ding, Y., Wang, H., Shen, H., Li, Z., Geng, J., Han, H., Cai, J., Li, X., Kang, W., Weng, D., 2003. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. *J. Pathol.* 200 (3), 282–289.
- Eyal, Nir, Lipsitch, Marc, Smith, Peter G., 2020. Human challenge studies to accelerate coronavirus vaccine licensure. *J. Infect. Dis.* <https://doi.org/10.1093/infdis/jiaa152>.
- Fu, Y., Cheng, Y., Wu, Y., 2020. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. *Virol. Sin.* 1–6.
- Gu, J., Han, B., Wang, J., 2020. COVID-19: gastrointestinal manifestations and potential

- fecal-oral transmission. *Gastroenterology* 382, 1708–1720. <https://doi.org/10.1056/NEJMoa2002032>.
- Guan, Wei-jie, Zheng-yi, N., et al., 2020. Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2002032>.
- Guan, G., Gao, L., Wang, J., Wen, X., Mao, T., Peng, S., Zhang, T., Chen, X., Lu, F., 2020a. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia. *Zhonghuaganzangbingzazhi = Zhonghuaganzangbingzazhi = Chinese journal of hepatology* 28 (2), E002.
- Guan, W.-j., Ni, Z.-y., Hu, Y., Liang, W.-h., Ou, C.-q., He, J.-x., Liu, L., Shan, H., Lei, C.-l., Hui, D.S., 2020b. Clinical Characteristics of 2019 Novel Coronavirus Infection in China. *Lancet* 395 (10223), 497–506.
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 2020a. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395 (10223), 497–506.
- Huang, P., Liu, T., Huang, L., Liu, H., Lei, M., Xu, W., Hu, X., Chen, J., Liu, B., 2020b. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. *Radiology* 295 (1), 22–23.
- Hui, D.S., Chow, B.K., Lo, T., Tsang, O.T.Y., Ko, F.W., Ng, S.S., Gin, T., Chan, M.T.V., 2019. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. *Eur. Respir. J.* 53 (4) (Apr).
- Hui, D.S., Azhar, E.I., Madani, T.A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T.D., Memish, Z.A., Drosten, C., 2020. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. *Int. J. Infect. Dis.* 91, 264–266.
- Imai, Y., Kuba, K., Penninger, J.M., 2008. The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice. *Exp. Physiol.* 93 (5), 543–548.
- Kampf, G., Todt, D., Pfaender, S., Steinmann, E., 2020. Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents. *J. Hosp. Infect.* 104, 246–251.
- Lee, P.-I., Hsueh, P.-R., 2020. Emerging threats from zoonotic coronaviruses—from SARS and MERS to 2019-nCoV. *J. Microbiol. Immunol. Infect.* 20, 30011–30016.
- Lee, N., Hui, D., Wu, A., Chan, P., Cameron, P., Joynt, G.M., Ahuja, A., Yung, M.Y., Leung, C., To, K., 2003. A major outbreak of severe acute respiratory syndrome in Hong Kong. *N. Engl. J. Med.* 348 (20), 1986–1994.
- Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y., Wong, J.Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J., Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H., Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang, Y., Shi, G., Lam, T.T.Y., Wu, J.T., Gao, G.F., Cowling, B.J., Yang, B., Leung, G.M., Feng, Z., 2020. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N. Engl. J. Med.* 382 (13), 1199–1207.
- Lu, H., Stratton, C.W., Tang, Y.W., 2020. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. *J. Med. Virol.* 92, 401–402.
- Masters, P.S., Perlman, S., 2013. Coronaviridae. In: Knipe, D.M., Howley, P.M. (Eds.), *Fields Virology*. Lippincott Williams & Wilkins, Philadelphia, PA, pp. 825–858.
- Meyer, N.J., Christie, J.D., 2013. Genetic heterogeneity and risk of acute respiratory distress syndrome. In: *Seminars in Respiratory and Critical Care Medicine*, pp. 459–474.
- Ng, D.L., Al Hosani, F., Keating, M.K., Gerber, S.I., Jones, T.L., Metcalfe, M.G., Tong, S., Tao, Y., Alami, N.N., Haynes, L.M., 2016. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of Middle East respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. *Am. J. Pathol.* 186 (3), 652–658.
- Ozaslan, Mehmet, Safdar, Muhamad, Halil Kilic, I., Khailany, Rozhgar A., 2020. Practical measures to prevent COVID-19: a mini-review. *J. Biol. Sci.* 20, 100–102.
- Paola, Stefanelli, Giovanni, Faggioni, Alessandra, Lo Presti, Stefano, Fiore, Antonella, Marchi, Eleonora, Benedetti, Concetta, Fabiani, Anna, Anselmo, Andrea, Ciammaruconi, Antonella, Fortunato, Riccardo, De Santis, Silvia, Fillo, Rosaria, Capobianchi Maria, Rita, Gismondo Maria, Alessandra, Ciervo, Giovanni, Rezza, Rita, Castrucci Maria, Florigio, Lista, ISS COVID-19 study group, 2020. Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe. *Euro Surveill.* 25 (13). <https://doi.org/10.2807/1560-7917.ES.2020.25.13.2000305>. (pii = 2000305).
- Peter, F., Lucy, F., Colin, R., Michael, F., 2020. Phylogenetic network analysis of SARS-CoV-2 genomes. www.pnas.org/cgi/doi/10.1073/pnas.2004999117.
- Phan, Tung, 2020. Genetic diversity and evolution of SARS-CoV-2. *Infect. Genet. Evol.* 81, 104260 (July).
- Phan, L.T., Nguyen, T.V., Luong, Q.C., Nguyen, T.V., Nguyen, H.T., Le, H.Q., Nguyen, T.T., Cao, T.M., Pham, Q.D., 2020. Importation and human-to-human transmission of a novel coronavirus in Vietnam. *N. Engl. J. Med.* 382 (9), 872–874.
- Rehman, S.U., Shafique, L., Ihsan, A., Liu, Q., 2020. Evolutionary trajectory for the emergence of novel coronavirus SARS-CoV-2. *Pathogens* 9 (3), 240. <https://doi.org/10.3390/pathogens9030240>.
- Ren, L.L., Wang, Y.-M., Wu, Z.-Q., Xiang, Z.-C., Guo, L., Xu, T., Jiang, Y.-Z., Xiong, Y., Li, Y.-J., Li, H., 2020. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chin. Med. J.* 133 (9), 1015–1024. <https://doi.org/10.1097/CM9.0000000000000722>.
- Rothan, H.A., Byrareddy, S.N., 2020. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. *J. Autoimmun.* 109, 102433. <https://doi.org/10.1016/j.jaut.2020.102433>.
- Rozhgar, A.M., Safdar, M., Ozaslan, M., 2020. Genomic characterization of a novel SARS-CoV-2. *Gene Rep.* 19, 100682.
- Singhal, T., 2020. A review of coronavirus disease-2019 (COVID-19). *Indian J. Pediatr.* 87 (4), 281–286.
- Sommerstein, R., Kochen Michael, M., Messerli Franz, H., Gräni, C., 2020. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? *J. Am. Heart Assoc.* 9 (7), e016509.
- Su, S., Wong, G., Shi, W., Liu, J., Lai, A.C., Zhou, J., Liu, W., Bi, Y., Gao, G.F., 2016. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. *Trends Microbiol.* 24 (6), 490–502.
- Takada, A., Kawaoka, Y., 2003. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. *Rev. Med. Virol.* 13 (6), 387–398.
- Tang, X., Wu, C., Li, X., Song, Y., Yao, X., Wu, X., et al., 2020. On the origin and continuing evolution of SARS-CoV-2. *Natl. Sci. Rev.* <https://doi.org/10.1093/nsr/nwaa036>.
- Thompson, B.T., Chambers, R.C., Liu, K.D., 2017. Acute respiratory distress syndrome. *N. Engl. J. Med.* 377 (6), 562–572.
- Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., 2020a. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 323 (11), 1061–1069.
- Wang, W., Tang, J., Wei, F., 2020b. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. *J. Med. Virol.* 92 (4), 441–447.
- Weiss, S.R., Navas-Martin, S., 2005. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. *Microbiol. Mol. Biol. Rev.* 69 (4), 635–664.
- WHO, 2020. <https://www.worldometers.info/coronavirus/>.
- Woo, P.C., Lau, S.K., Lam, C.S., Lau, C.C., Tsang, A.K., Lau, J.H., Bai, R., Teng, J.L., Tsang, C.C., Wang, M., 2012. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and delta coronavirus. *J. Virol.* 86 (7), 3995–4008.
- Xiao, F., Tang, M., Zheng, X., Li, C., He, J., Hong, Z., Huang, S., Zhang, Z., Lin, X., Fang, Z., 2020. Evidence for Gastrointestinal Infection of SARS-CoV-2.
- Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir. Med.* 8 (4), 420–422.
- Yuefei, J., Haiyan, Y., Wangquan, J., Weidong, W., Shuaiyi, C., Weiguang, Z., Guangcai, D., 2020. Virology, epidemiology, pathogenesis, and control of COVID-19. *Viruses* 12 (4), 372. <https://doi.org/10.3390/v12040372>.
- Zaki, A.M., Van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N. Engl. J. Med.* 367 (19), 1814–1820.
- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., 2020. A novel coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* 382, 727–733.
- Zou, L., Ruan, F., Huang, M., Liang, L., Huang, H., Hong, Z., Yu, J., Kang, M., Song, Y., Xia, J., 2020. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. *N. Engl. J. Med.* 382 (12), 1177–1179.